Our mission

To harness the power of drug development & manufacturing to transform molecules into medicines.

Our values


Our actions demonstrate respect for our customers, business partners, employees, and the communities where we operate. We honour our commitments and hold ourselves accountable.


We challenge our scientific knowledge and diverse talent to explore and develop new ways of solving industry problems while adding value to our customers and stakeholders.


We combine rigorous execution with agility and flexibility to deliver high-quality results with timing and excellence.


Collaboration is at the heart of everything we do. We understand working together only makes things better, faster, and greater. We trust each other, empower our teams, and encourage and embrace diverse viewpoints.



We attract diverse talent that represents the world we live in. We foster an environment where everyone feels valued, empowered and encouraged to succeed.

Our vision

To be the leading development and commercialization partner
in pharmaceuticals and biotechnology.



Our locations

Click on a location to learn about our capabilities.

  • Devens, MA, USA
  • North Andover, MA, USA
  • Wayne, PA, USA
  • West Deptford, NJ, USA
  • Edinburgh, UK
  • Annan, UK
  • Cambridge, UK
  • Yantai, China

Our certifications


FDA Inspected

MHRA Inspected


Leadership team

Niek Stapel, CEO

Niek Stapel has served as Chief Executive Officer since November 2020. He has over 30 years of experience in the specialty and fine chemicals business . Prior to joining Veranova, he was responsible for the $1.0b Nouryon Pulp and Performance Chemicals Business Unit and was a member of the Nouryon Leadership Team. Nouryon was previously the Chemicals Division of AkzoNobel, now owned by private equity firm Carlyle. He served in various general management positions with full P&L responsibility ($100m-$1.0b) in three continents (The Netherlands, Sweden, Malaysia/Singapore and the US). He has proven success of establishing top line growth, expanding market shares and increasing margins in differentiating businesses. He also successfully executed various restructuring projects and turn around programs in a number of businesses.

Niek holds a master’s degree in Business Administration and General Economics from the University of Groningen in The Netherlands and a post-graduate Controllers degree from the University of Amsterdam in the Netherlands. He is a native from the Netherlands and also holds the US citizenship. Niek Stapel is fluent in Dutch, English and German, and conversational in French.

Andrew Wesztergom, SVP, CFO

Andy Wesztergom has served as SVP of Finance and Chief Financial Officer since January 2019. Andy leads all aspects of the accounting and finance function as well as Human Resources and IT. Andy has spent the majority of his career working for large international manufacturing companies, both public, private and private investor backed, focusing on specialty chemicals and metals. Andy holds an MBA from Temple University with a concentration in Strategic Management, and a Bachelor of Business Administration in Accounting and Finance.

Nick Shackley, SVP, Generics & Strategic Marketing

Nick Shackley has served as SVP, Generics & Strategic Marketing since September 2020. He joined in November 2017 as VP, CDMO / Innovators. From August 2011 to October 2017, Nick worked for Aceto Corporation as Global Vice President, Active Ingredients and Intermediates. From January 2008 to June 2011, he worked for BASF Corporation as Vice President, Pharma Ingredients and Services and prior to 2008, Nick held technical and commercial roles in Zeneca, Avecia and Cambrex.

Nick served on the Board of SOCMA from 2003 – 2011. Nick holds a degree in Chemical Engineering from Imperial College, University of London.

Ken Zrebiec, SVP Manufacturing Operations

Ken Zrebiec has served as SVP, Manufacturing Operations since December 2020. With over 20 years of experience in the production of active pharmaceutical ingredients, Ken has proven leadership in site management, supply chain, project management, and environmental, health, and safety. Prior to Veranova, Ken held senior operational roles with Siegfried in the US and Switzerland and was the Director of Supply Chain at Endo Pharmaceuticals.

Ken has been on the SOCMA Board of Governors since 2018 and has been a member of the SOCMA Executive Board since 2020. Ken holds a B.S. degree in Chemical Engineering and an MBA in Operations Management from the University of Delaware.

Shawn D. Walker, SVP Development Operations & CTO

Shawn Walker has served as SVP Development Operations and Chief Technology Officer since October 2019. He is accountable for the global R&D organization encompassing Chemical & Analytical Development, Solid Form Sciences and Particle Engineering, Generics Finished Dosage Form Development, New Product Introduction and Operations Excellence. Previously, Shawn worked at Amgen, one of the world’s leading biotechnology companies, where he served in roles of increasing responsibility within process development, contributing to the advancement of synthetic and hybrid modalities across all phases of development and therapeutic areas. This included contributions to many clinical drug candidates and commercial products, including Corlanor, Kyprolis, Parsabiv and Lumakras. Shawn has been actively engaged in the scientific community through publications, patents, and presentations, and his research has been cited extensively in the chemical literature. He was recognized by the American Chemical Society with an Industrial Young Investigator Award and has served on a number of professional committees including the Board of Directors of the Enabling Technologies Consortium and the Steering Committee for the Machine Learning for Pharmaceutical Discovery & Synthesis Consortium. Shawn obtained a B.Sc. in Chemistry from McGill University, a Ph.D. in Organic Chemistry from the University of British Columbia and completed post-doctoral research at the Massachusetts Institute of Technology.

Ross Oehler, SVP, General Counsel

Ross Oehler has headed the Legal and Intellectual Property functions since May 2013. He has practiced law in both the private and corporate sectors and, for the last 30 years, focused on the biopharmaceutical and applied chemistry industries, holding positions of increasing responsibility in Legal and IP with Sanofi-Aventis (formerly Rhône-Poulenc Rorer) and Cephalon, Inc., before assuming his current role with Veranova supporting all functions in the business.

Ross is admitted to practice in Pennsylvania, the U.S. Patent and Trademark Office, and has been involved in numerous IP and commercial disputes in US Federal Courts, the International Trade Commission, post-grant review proceedings in the US and European Patent Offices, and in several courts throughout Europe. Ross is a member of the Association of Corporate Counsel, the Association of Corporate Patent Counsel, and the Intellectual Property Owners Association, where he served on the Board of Directors.

Featured insights from our experts

Read more

The importance of chirality in API development

The chirality of a molecule can influence key pharmacological activities, which impact a drug’s tolerability, safety, and bioavailability.

Ultra-pure synthetic cannabidiol (CBD)

We’re utilising our scientific and manufacturing expertise to develop and commercialize ultra-pure synthetic…

Early form screening strategies to accelerate candidate selection

Failure to select a successful candidate can be expensive in terms of both time and money.

Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us